Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

O, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events (MACE), including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 23, 2014 ViaDerma, Inc ... company devoted to bringing new products to market, ... , ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... Today, Nerium International, a leader in ... its “Reflect Your Youth” contest, an effort launched to ... difference in their skin since using Nerium’s product line, ... life as a result of their newfound confidence. , ... by Nerium International to inspire conversations focused on the ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2
... Cephalon, Inc.,(Nasdaq: CEPH ) today announced its ... to an Abbreviated New Drug Application (ANDA),submitted to ... Watson,Laboratories, Inc., requesting approval to market and sell ... In its Notice,Letter, Watson alleges that the U.S. ...
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the ... to a record $2.55 billion in the first quarter,of ... translation,increased revenues by 4%, and acquisitions, net of divestitures, ... were $.53 in 2008,versus $.31 in the year-ago period. ...
... Munich, Germany, April 24, 2008 / b3c ... group at Stanford University are working on a project ... are introduced in a statistically expected and controlled ratio ... ,Sloning will utilize its core technology, Slonomics™, a unique ...
Cached Biology Technology:Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 2Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 2Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 3Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 4Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 5Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 6Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 7Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 8Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 9Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 10Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 11Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 12Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and Operating Performance 13Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library 2
(Date:10/29/2014)... pollutants released by unconventional oil and gas production are ... today in the open access journal Environmental Health ... were found. The study is the first to be ... production sites and could be used to supplement official ... from reserves that do not readily flow to the ...
(Date:10/29/2014)... largest study of its kind to date, researchers have ... heighten the risk for autism. Joseph Buxbaum, Ph.D., Icahn ... Mark Daly, Ph.D., Broad Institute of Harvard and MIT, ... from affected children, parents and unrelated people. They identified ... to the risk for autism spectrum disorder (ASD) – ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... New tires allow race cars to take tight turns ... advantages: They are not necessary for basic flight but help ... escape a predator, you don,t have to be fast, you ... world authority on animal behavior, ecology and evolution and the ...
... deliveries and having them at term but before completing ... likely to have a baby with serious complications including ... , UAB researchers, led by Alan T.N. Tita, M.D., ... and Gynecology Division of Maternal-Fetal Medicine, and colleagues reported ...
... remarkable new discovery shows the four-eyed spookfish to be the ... to focus light in its eyes. Professor Julian Partridge ... years of vertebrate evolution, and many thousands of vertebrate species ... have solved the fundamental optical problem faced by all eyes ...
Cached Biology News:Hind wings help butterflies make swift turns to evade predators, study finds 2Repeat C-section before 39 weeks raises risk of neonatal illness 2Spookfish uses mirrors for eyes 2
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: